A therosclerotic cardiovascular (CV) disease is a major health concern affecting more than 200 million adults worldwide (1) . Lower extremity peripheral artery disease (PAD) is considered a manifestation of systemic atherosclerosis that affects the arteries of the lower limbs. Despite advancements in the diagnosis and treatment in recent decades, 5% to 10% of patients with PAD have recurrent events and millions die from CV disease each year (2) . Antithrombotic medications have been proven to reduce CV morbidity and mortality in a number of scenarios including acute coronary syndrome, atrial fibrillation, and percutaneous coronary intervention (3) (4) (5) (6) (7) . Additionally, the use of statin medications is considered a cornerstone therapy to reduce the occurrence of major adverse CV events in patients with stable atherosclerotic disease (8, 9) .
Although the evidence base for PAD is considerably less developed than for other conditions, there has been burgeoning interest in understanding this highrisk population. This review outlines the inherent CV risks of patients with PAD, risk reduction strategies, antithrombotic clinical trial data, and opportunities for the CV community to generate evidence in realworld settings and translate that evidence into practice as new therapies become available.
PAD POPULATION AND TREATMENT OPTIONS
Most patients with PAD are asymptomatic, and those
with symptoms can present with a myriad of symptoms including atypical leg pain, intermittent claudication (leg pain that occurs with exertion and improves with rest), ischemic rest pain, ulceration, or gangrene (10). This symptom presentation often dictates which physician specialty (primary care, cardiology, vascular surgery, radiology, or vascular medicine) evaluates and treats the patient. An anklebrachial index (ABI) is the most frequently used diagnostic test to determine the presence of PAD, and the degree of hemodynamic abnormality is often used to determine treatment strategies, in addition to symptom presentation.
In the United States, the medical treatment of patients with PAD has traditionally involved antiplatelet monotherapy (e.g., aspirin or clopidogrel) and moderate-to high-intensity statin medication to reduce CV risk over time (10). Whereas PAD is generally considered a coronary artery disease (CAD) risk equivalent, the prescription rates of antiplatelet and statin medications in patients with PAD are significantly lower when compared with patients with CAD. As such, there is significant opportunity to improve the prescription rates and adherence to these important risk reduction medications in patients with PAD (11, 12) . In patients with symptoms despite background medical therapy, cilostazol and supervised Determination that will reimburse providers for supervised exercise training in patients with intermittent claudication (15) .
There are few proven medical therapies for patients with critical limb ischemia (CLI), the most severe form of the disease. In these patients with limb-threatening ischemia, noninvasive and invasive imaging is recommended to define the burden and severity of obstructive disease, and revascularization is frequently recommended to preserve limb function and mobility (16) . Heterogeneity exists in the application of these diagnostic and interventional strategies across the country and disparities in care have been reported (17, 18) .
Nevertheless, the mortality rate of patients with CLI at 1 year is nearly 50%, signaling the need for immediate attention to this extreme risk cohort of patients (19) .
CV AND LIMB EVENTS IN PAD
The risk of major adverse CV and limb events has been described commonly over the last decade ( Figure 1 (21) . Additionally, the risk of major adverse limb events (typically defined as major amputation or surgical intervention) varies from 2% to 10% annually depending on age, symptom classification, concomitant medical therapy, and prior revascularization procedures (22) .
During the last 2 decades, the occurrence of major amputation of the lower extremities due to PAD has decreased significantly in the United States; however, it remains an important public health concern because mortality rates are nearly 50% at 1 year and 70% at 3 years after major amputation (23, 24) . In a simultaneous presentation, the PAD cohort from COMPASS was equally effective (36 
CENTRAL ILLUSTRATION Mechanisms of Antithrombotic Medications and Clinical Endpoints Important to Patients With Peripheral Artery Disease
In aggregate, these trial results provide some insight into how the different targets of these thera- 
GENERATING EVIDENCE IN REAL-WORLD SETTINGS
Despite increased focus of clinical research on patients with PAD, critical questions remain unanswered in this high-risk population. It is imperative that we embed studies within standard practice and answer these questions using data generated during patient care (33) . The clinical community must continue to develop the concept of a learning health system that has been widely discussed and broadly defined by the Institute of Medicine as follows: "science, informatics, incentives, and culture are aligned for continuous improvement and innovation, with best practices seamlessly embedded in the delivery process and new knowledge captured as an integral by-product of the delivery experience" (38). But learning health systems are not enough. Networks of learning health systems will be required to perform meaningful and pragmatic research, to evaluate treatment strategies, and to study the efficacy and safety of novel drugs and devices. The PAD community must also embrace and use the national evidence generation infrastructure that is in the process of being constructed to study diseases and therapeutics (Figure 3) . Key partnerships between academic vascular specialists, industry representatives, electronic health record/health information A similar data structure that includes methods to identify a cohort within the electronic health record system and follow patients longitudinally to implement effective antithrombotic therapies and measure patient-reported and hard CV outcomes. This could be considered the "computable phenotype" for PAD patients.
Real-time feedback systems to learn and improve care.
For patients with PAD, there has been significant heterogeneity in the trial definitions of patients and are used across centers. These data are then transmitted to the electronic health record, disease-specific and/or procedural registries (ACC PVI, SVS VQI), common data models (e.g., PCORnet), and administrative claims datasets (private and public health insurance companies). Using data transfer agreements that include query tools, the data is then used to populate: 1) clinical trial databases; 2) comparative effectiveness observational study databases; and/or 3) larger national registries used for quality improvement and/or drug/device safety and surveillance. Study funding for these entities can occur via public (e.g., NIH, PCORI, FDA, NEST) or private (e.g., industry, health system) means. The entire process, when used for drug/device approval or safety/surveillance, is governed by regulatory agencies (i.e., U.S. FDA). 
TRANSLATING EVIDENCE INTO PRACTICE
While it is scientifically feasible to study patients in broad learning health systems, the real question is how to translate evidence into practice so that available, effective, and safe therapies such as the patel@duke.edu.
